1 / 25

Umbilical Cord Blood Transplantation in Pediatric Patients with Malignant Diseases

Umbilical Cord Blood Transplantation in Pediatric Patients with Malignant Diseases. Results of a Prospective, Multi-Institutional NHLBI Sponsored Trial.

vasilis
Download Presentation

Umbilical Cord Blood Transplantation in Pediatric Patients with Malignant Diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Umbilical Cord Blood Transplantation in Pediatric Patients with Malignant Diseases Results of a Prospective, Multi-Institutional NHLBI Sponsored Trial J Kurtzberg, SL Carter, JE Wagner, LA Baxter-Lowe, D Wall, N Kapoor, E Guinan, S Feig, E Wagner, NA Kernan on behalf of the COBLT Steering Committee

  2. Overview of the COBLT Study • Prospective, multi-institutional study sponsored by the NHLBI. • 3 banks: • Duke J Kurtzberg • UCLA J Fraser • CHOC/GT M Cairo • Created inventory of approx 8,000 units • 71 % of transplants used COBLT units • Transplantation study: Strata for adults, peds ID, metabolic ds & peds malignancies.

  3. The Transplantation Study • Common protocol for preparative regimen, GvHD prophylaxis and supportive care. • Common criteria for evaluation of risk status at study entry, donor selection, engraftment, GvHD, infection and causes of death.

  4. Study End Points • Primary Endpoint • 180 day survival • Secondary Endpoints • Disease-free survival • Incidence of neutrophil engraftment • Incidence of platelet engraftment • Incidence of acute and chronic GVHD • Incidence of relapse • Analysis of high resolution HLA typing and effect on outcomes.

  5. Definitions • Original HLA Matching • Low resolution DNA based typing for Class I, A and B, High resolution DNA typing for Class II, DRB1 • Retrospective (final) HLA Matching • High resolution DNA typing for A, B, DRB1 • Engraftment • ANC 500/uL with >90% donor chimerism by day 42

  6. Patient Eligibility • Pediatric Patients between 1-18 years • Hematological malignancies • Exclude CML blast crisis • Exclude ALL relapse • No related donor • UCB donor delivering >10e7 cells/kg, matching at 4/6 HLA loci by low resolution typing at Class I, or 3/6 with high resolution matching, 1 allele at A, B, DRB1.

  7. Treatment • Preparative Regimen • TBI 1350 • Cyclophosphamide 120 • Horse ATG 90 • GvHD Prophylaxis • Cyclosporine • Methyprednisolone • Supportive Care • Anti viral, fungal and PCP prophylaxis • Antigen/DNA monitoring for CMV • G-CSF from day 0 • IVIG prophylaxis

  8. Demographics 191 subjects transplanted between 2000-2003 Median Age: 7.7 (0.9 – 17.9) years Median Weight: 25.9 (7.5-118.4) kg 61% Males 58% White/38% Other/5% Unknown 51% CMV+ 77% High Risk Median pre cryo cell dose:5.2x10e7/kg Median CD34 cell dose: 1.52x10e5/kg

  9. HLA Matching at HLA A, B & DRB1 1 Percent based on number of patients that have been retrospectively typed. 2 Percent based on number enrolled.

  10. 1.0 1.0 0.8 0.8 0.6 0.6 Probability Probability 0.4 0.4 0.2 0.2 CINC CINC 0.0 0.0 1-KM 1-KM 0 20 40 60 80 100 0 2 4 6 8 10 12 Days Post-Transplant Months Post-Transplant Engraftment Cumulative Incidence (CINC) and 1-Kaplan-Meier (1-KM) Neutrophil Engraftment Platelet Engraftment (>50K/mm3) 153/189 at d42 CI 75.1 (95%CI 69.3-81-5) 107/189 at d180 CI 50.5 (95% CI 42.5-58.7)

  11. Multivariate Analysis Neutrophil Engraftment 1 Original HLA Match 5/6 versus 4/6

  12. 1.0 1.0 0.8 0.8 0.6 0.6 Probability Probability 0.4 0.4 0.2 0.2 0.0 0.0 CINC CINC 0 6 12 18 24 0 20 40 60 80 100 120 140 160 1-KM 1-KM Months Post-Transplant Days Post-Transplant Graft Versus Host Disease Cumulative Incidence (CINC) and 1-Kaplan-Meier (1-KM) Acute GVHD Grades III/IV Chronic GVHD 70% Limited CI at d100 18.6% (95% CI 12.2-23.8) CI at 1 yr 20.4% (95% CI 14.6-26.4)

  13. Multivariate Analysis Acute GVHD Grades III/IV 1 Original HLA Match 5/6 or 6/6 versus 3/6 or 4/6

  14. 1.0 0.8 0.6 Probability 0.4 0.2 CINC 0.0 1-KM 0 6 12 18 24 30 36 42 Months Post-Transplant Relapse Cumulative Incidence (CINC) and 1-Kaplan-Meier (1-KM) CI at 1 year 19.1 (95% CI 13.8-24.8)

  15. Causes of Death

  16. Overall Survival 1.0 | 0.8 | 0.6 | | | | | | | | | | | | | | | | | | | | | | | | | | Probability | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 0.4 180 days 67.4 (95% CI 60-7-74.1) 1 yr 57.3 (95%CI 50.2-64.3) Median 24 months 0.2 0.0 0 6 12 18 24 30 36 42 Months Post-Transplant N=191

  17. 1.0 1.0 1.0 | | | 0.8 0.8 0.8 | | | | | | | | | | | | | 0.6 0.6 0.6 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Probability Probability Probability | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 0.4 0.4 0.4 | | | | | | | | | | | | | 0.2 0.2 0.2 P<0.01 P=0.65 P=0.30 0.0 0.0 0.0 0 6 12 18 24 30 36 42 0 6 12 18 24 30 36 42 0 6 12 18 24 30 36 42 Months Post-Transplant Months Post-Transplant Months Post-Transplant Male, N=116 Male, N=102 M/M or F/F, N=96 Female, N=75 M/F or F/M, N=91 Female, N=85 Overall Survival Recipient Gender Donor Gender Donor/Recipient Gender | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

  18. 1.0 0.8 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 0.6 Probability | | | | | | | | 0.4 | | | | | | | | | | | | | | | | | | | 0.2 P<0.01 0.0 Positive, N=98 0 6 12 18 24 30 36 42 Negative, N=92 Months Post-Transplant Overall Survival Recipient Cytomegalovirus Serostatus | | | | | | | | | |

  19. 1.0 1.0 | 0.8 0.8 | | | | | | | | | 0.6 | | | | | | | | | | | | | | | | | 0.6 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Probability | Probability | | | | | | | | | | | | | | | | | | | | | | | | | 0.4 0.4 | 0.2 0.2 P=0.03 P=0.73 0.0 0.0 0 6 12 18 24 30 36 42 0 6 12 18 24 30 36 42 <2.5, N=17 <1.51, N=69 Months Post-Transplant >=1.51, N=91 2.5-5.0, N=73 Months Post-Transplant 5.0-7.5, N=54 >7.5, N=47 Overall Survival Pre-Cryopreserved TNC (x107/kg) Pre-Cryopreserved CD34+ (x105/kg) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

  20. 1.0 1.0 0.8 0.8 | | 0.6 0.6 | | | | | | | | | | | | | | | | | | | | | | | | | | | | Probability Probability | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 0.4 0.4 0.2 0.2 P=0.92 P=0.37 0.0 0.0 5/6, N=59 5/6, N=40 0 6 12 18 24 30 36 42 0 6 12 18 24 30 36 42 4/6, N=110 4/6, N=77 Months Post-Transplant Months Post-Transplant Overall Survival Original HLA Match Retrospective HLA Match | | | | | | | | | | | | | | | |

  21. Multivariate Analysis For Survival 1 Time Dependent Covariate

  22. Summary • The COBLT Study represents the first prospective, multi-institutional study of cord blood transplantation • Standard treatment protocol • Standard supportive care • Standard outcome definitions and assessments • Analysis of retrospective high resolution HLA typing on outcomes (with 34% of patients having greater disparity than original typing)

  23. Conclusions • Incidence of engraftment is 75% which correlated with nucleated cell dose and donor gestational age. • Incidence of acute grade III/IV acute GVHD was 19%; chronic GVHD was 20% (70% limited) and GVHD was cause of death in 30% of fatalities. • Incidence of relapse was 25% (77% of pts were high risk).

  24. Conclusions • Overall survival was 55% with early engraftment, recipient CMV seronegative status and male gender being favorable risk factors. • Notably, level of HLA match (original or high resolution) and risk status at diagnoses did not impact survival .

  25. Acknowledgements • Cardinal Glennon Children's Hospital - Dr. Michael Kelly • Case Western Reserve University Hospital - Dr. Mary Laughlin • Children's Hospital – Los Angeles - Dr. Neena Kapoor • Children's Hospital – New Orleans - Dr. Lolie Yu • Children's Hospital – Orange County - Dr. Steven Neudorf • Children's Hospital – Philadelphia - Dr. Nancy Bunin • Children's Hospital – Pittsburgh - Dr. Rakesh Goyal • Children's Medical Center of Dallas - Drs. Victor Aquino & Donna Wall • Children's Mercy Hospital - Dr. Andrew Gilman • Children's National Medical Center - Dr. Naynesh Kamani • City of Hope National Medical Center - Dr. Joseph Rosenthal • Dana Farber Cancer Institute - Drs. Eva Guinan & Leslie Lehmann • DeVos Children's Hospital - Dr. Daniel Pietryga • Fred Hutchinson Cancer Research Center - Dr. Colleen Delaney • Hackensack University Medical Center - Drs. Joel Brochstein & Stuart Goldberg • Indiana University Cancer Center - Dr. Paul Haut • North Texas Hospital for Children - Dr. Joel Weinthal • Roswell Park Cancer Institute - Drs. Philip McCarthy & Barbara Bambach • Schneider Children's Hospital - Dr. Indira Sahdev • Texas Transplant Institute - Drs. Carlos Bachier & Donna Wall • University of California, Los Angeles - Dr. Stephen Feig • University of California, San Francisco - Drs. Morton Cowan & Biljana Horn • University of Florida - Dr. Steven Hunger • University of Minnesota - Dr. John Wagner • University of Rochester - Drs. John Horan & Jane Liesveld • Vanderbilt University - Dr. Haydar Frangoul • The EMMES Corporation – Dr. Shelly Carter& Mr. Adam Mendizabal • National Heart, Lung and Blood Institute – Dr. Luiz Barbosa, Ms. Liz Wagner & Dr. LeeAnn Jensen • Dr. Nancy A. Kernan, • Steering Committee Chair

More Related